* Hank Brown, CU president emeritus, announces retirement from university
   
* Faculty Council: Proposed early retirement incentive could be greater
   
* Tuition benefit all in the family at UCCS
   
* Five questions for Jason Katzman
   
* People
   
* Forum
   
* Did you know...
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  CU-Boulder contingent makes trek to Copenhagen climate conference
 
  UCCS
  University to program downtown art gallery
 
  UC DENVER
  Gift from Wal-Mart will help small Colorado communities go green
 
  ANSCHUTZ MEDICAL CAMPUS
  School of Pharmacy researcher receives funding from Michael J. Fox Foundation
 
  TECH TRANSFER
  Soligenix options CU vaccine technology
 
   Home
   Newsletter Archive
 
Download Newsleter in PDF
 
Share your thoughts
  FORUM
Share your opinion in a Letter to the Editor

CONTACT US
Send your thoughts and suggestions for the Newsletter
   
   
   
   
   
   
   

News from the CU system - Tech Transfer

Soligenix options CU vaccine technology

Soligenix Inc. recently announced that it has formed a consortium to develop thermostable technology to advance its RiVax and other rapidly acting vaccines.

Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to support this work. As part of the initiative, Soligenix has executed an option agreement with the University of Colorado covering novel technology to develop vaccines that can maintain stability at elevated temperatures. This new technology will form the cornerstone of the company's research and development effort, which will involve the development of formulation and manufacturing processes for vaccines, including RiVax, that are stable at elevated temperatures.

"Each of our academic and industry consortium members brings impressive expertise to our vaccine stabilization program," said Dr. Robert N. Brey, Ph.D., chief scientific officer of Soligenix. "This association has the potential to address the practical issue of long-term stability in stockpiled biodefense vaccines, using a technology basis that can ultimately be applied to other commercial vaccine products."

"Our progress with RiVax has been notable, and this grant award further validates the previous work and merits of our biodefense program," stated Christopher J. Schaber, Ph.D., president and CEO of Soligenix. "We look forward to working with our outstanding partners in this consortium to develop thermally stable biodefense vaccines to address two high-priority biothreats."

Bookmark - Print - Share

 
Previous Tech Transfer Stories

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app